Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Meclizine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Meclizine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Meclizine | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | | Meclizine | hsa00500 | Starch and sucrose metabolism | 8.89E-07 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Meclizine | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Meclizine | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | Meclizine | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Meclizine | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | | Meclizine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Meclizine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Meclizine | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | | Meclizine | hsa00730 | Thiamine metabolism | 4.16E-06 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Meclizine | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Meclizine | hsa00970 | Aminoacyl-tRNA biosynthesis | 4.54E-04 | 3 | O95363, P54136, Q15046 | FARS2, RARS1, KARS | More | | Meclizine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Meclizine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Meclizine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Meclizine | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Meclizine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa01523 | Antifolate resistance | 1.43E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | Meclizine | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Meclizine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Meclizine | hsa03013 | RNA transport | 8.19E-04 | 7 | Q15287, Q9UBU9, P35658, P63279, P55884, O15371, P20042 | RNPS1, NXF1, NUP214, UBE2I, EIF3B, EIF3D, EIF2S2 | More | | Meclizine | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Meclizine | hsa03020 | RNA polymerase | 5.24E-06 | 4 | P24928, P62487, Q9GZM3, P52435 | POLR2A, POLR2G, POLR2J2, POLR2J | More | | Meclizine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Meclizine | hsa03040 | Spliceosome | 1.81E-06 | 16 | O43143, O60508, P08579, Q15427, P26368, P38159, P61978, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, SF3B4, U2AF2, RBMX, HNRPK, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Meclizine | hsa03060 | Protein export | 1.43E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Meclizine | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | | Meclizine | hsa04014 | Ras signaling pathway | 1.13E-02 | 9 | P42338, P20827, P49767, P08069, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, IGF1R, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Meclizine | hsa04015 | Rap1 signaling pathway | 5.88E-04 | 13 | P20827, P49767, P08069, Q96FS4, P11215, P25116, Q8TEU7, Q13009, Q7LDG7, P42338, P08514, P17252, P19174 | EFNA1, VEGFC, IGF1R, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, RASGRP2, PIK3CB, ITGA2B, PRKCA, PLCG1 | More | | Meclizine | hsa04020 | Calcium signaling pathway | 6.50E-04 | 6 | Q96DU7, P45880, Q13557, P21860, P51828, P23634 | ITPKC, VDAC2, CAMK2D, ERBB3, ADCY7, ATP2B4 | More | | Meclizine | hsa04022 | cGMP-PKG signaling pathway | 3.25E-03 | 8 | Q99941, P18848, P23634, Q8WYR1, P51828, P05141, P45880, P0DP24 | CREBL1, ATF4, ATP2B4, PIK3R5, ADCY7, SLC25A5, VDAC2, CALM2 | More | | Meclizine | hsa04062 | Chemokine signaling pathway | 1.43E-04 | 17 | P25024, P25025, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P49841, Q8WYR1 | CXCR1, CXCR2, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, GSK3B, PIK3R5 | More | | Meclizine | hsa04064 | NF-kappa B signaling pathway | 2.99E-02 | 7 | O00463, P14778, Q13077, Q16548, Q8WV28, P24522, P09341 | TRAF5, IL1R1, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | | Meclizine | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04071 | Sphingolipid signaling pathway | 4.61E-03 | 7 | Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | Meclizine | hsa04110 | Cell cycle | 1.97E-05 | 7 | P06493, O60566, O75293, P30304, P33981, P42773, P01106 | CDK1, BUB1B, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Meclizine | hsa04114 | Oocyte meiosis | 3.19E-03 | 5 | P51812, Q02750, P16298, Q17RY0, P08069 | RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | | Meclizine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Meclizine | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | | Meclizine | hsa04150 | mTOR signaling pathway | 7.74E-03 | 4 | P08069, Q02750, Q9NQL2, P51812 | IGF1R, MAP2K1, RRAGD, RPS6KA3 | More | | Meclizine | hsa04151 | PI3K-Akt signaling pathway | 1.67E-03 | 18 | P62753, P42338, P43657, O43521, P27348, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P18848, O00141, Q6ZUJ8, P30281 | RPS6, PIK3CB, P2RY5, BCL2L11, YWHAQ, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, ATF4, SGK, PIK3AP1, CCND3 | More | | Meclizine | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04210 | Apoptosis | 4.66E-03 | 7 | O76075, P01375, Q9NR28, O75460, Q16548, O43521, P18848 | DFFB, TNF, DIABLO, ERN1, BCL2A1, BCL2L11, ATF4 | More | | Meclizine | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04213 | Longevity regulating pathway - multiple species | 1.66E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Meclizine | hsa04217 | Necroptosis | 3.89E-04 | 9 | P01375, P48023, Q14765, P15104, P05141, P01584, P0C0S5, Q99878, Q9H444 | TNF, FASLG, STAT4, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CHMP4B | More | | Meclizine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | Meclizine | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.98E-02 | 4 | P51828, Q99941, Q13557, P23634 | ADCY7, CREBL1, CAMK2D, ATP2B4 | More | | Meclizine | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | Meclizine | hsa04340 | Hedgehog signaling pathway | 4.15E-03 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Meclizine | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Meclizine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Meclizine | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Meclizine | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Meclizine | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | | Meclizine | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Meclizine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | | Meclizine | hsa04612 | Antigen processing and presentation | 2.40E-02 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Meclizine | hsa04613 | Neutrophil extracellular trap formation | 6.94E-04 | 18 | O60603, P05164, P08246, Q9UM07, P04908, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Meclizine | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | | Meclizine | hsa04640 | Hematopoietic cell lineage | 4.71E-03 | 5 | P21926, P07766, P01730, P06127, P09564 | CD9, CD3E, CD4, CD5, CD7 | More | | Meclizine | hsa04650 | Natural killer cell mediated cytotoxicity | 1.36E-05 | 13 | P16298, P50591, P01375, P78314, P06239, O60880, P20963, Q02750, Q13241, P26718, O75015, P26717, P26715 | PPP3CB, TNFSF10, TNF, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Meclizine | hsa04657 | IL-17 signaling pathway | 7.74E-04 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Meclizine | hsa04658 | Th1 and Th2 cell differentiation | 3.62E-04 | 9 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB | More | | Meclizine | hsa04659 | Th17 cell differentiation | 5.44E-05 | 14 | P25963, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P84022, Q13485, P08238, P07766, P09693, P20963 | NFKBIA, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Meclizine | hsa04660 | T cell receptor signaling pathway | 3.59E-04 | 12 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Meclizine | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Meclizine | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Meclizine | hsa04668 | TNF signaling pathway | 3.36E-03 | 5 | Q99941, P18848, P01584, P20333, O95429 | CREBL1, ATF4, IL1B, TNFRSF1B, BAG4 | More | | Meclizine | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | | Meclizine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Meclizine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Meclizine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Meclizine | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Meclizine | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Meclizine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Meclizine | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.74E-02 | 3 | P01584, P51828, Q13557 | IL1B, ADCY7, CAMK2D | More | | Meclizine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Meclizine | hsa04911 | Insulin secretion | 1.48E-02 | 3 | P51828, Q99941, Q13557 | ADCY7, CREBL1, CAMK2D | More | | Meclizine | hsa04913 | Ovarian steroidogenesis | 1.16E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa04914 | Progesterone-mediated oocyte maturation | 5.89E-03 | 4 | P08069, Q17RY0, P51812, Q02750 | IGF1R, CPEB4, RPS6KA3, MAP2K1 | More | | Meclizine | hsa04915 | Estrogen signaling pathway | 4.72E-02 | 4 | Q99941, P51828, P07900, P11142 | CREBL1, ADCY7, HSP90AA1, HSPA8 | More | | Meclizine | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | Meclizine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Meclizine | hsa04925 | Aldosterone synthesis and secretion | 5.19E-03 | 4 | Q99941, P51828, Q13557, P23634 | CREBL1, ADCY7, CAMK2D, ATP2B4 | More | | Meclizine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Meclizine | hsa04932 | Non-alcoholic fatty liver disease | 1.52E-05 | 10 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, Q16718, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA5, SDHD | More | | Meclizine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.11E-03 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | | Meclizine | hsa04934 | Cushing syndrome | 3.48E-03 | 4 | Q99941, P51828, O15169, Q13557 | CREBL1, ADCY7, AXIN1, CAMK2D | More | | Meclizine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Meclizine | hsa04971 | Gastric acid secretion | 1.48E-02 | 3 | P51828, P15311, Q13557 | ADCY7, VIL2, CAMK2D | More | | Meclizine | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Meclizine | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Meclizine | hsa05010 | Alzheimer disease | 1.70E-03 | 11 | Q92542, P05496, P13073, P12074, O75460, P0DP24, P01584, P18848, O15169, P05141, P45880 | NCSTN, ATP5G1, COX4I1, COX6A1, ERN1, CALM2, IL1B, ATF4, AXIN1, SLC25A5, VDAC2 | More | | Meclizine | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Meclizine | hsa05016 | Huntington disease | 1.05E-04 | 8 | P13073, Q9GZM3, P24928, P62487, P52435, P05141, Q9NYC9, O75460 | COX4I1, POLR2J2, POLR2A, POLR2G, POLR2J, SLC25A5, DNAH9, ERN1 | More | | Meclizine | hsa05020 | Prion disease | 1.37E-03 | 11 | P01584, P46531, P11142, Q16718, O14521, P05496, P12074, P45880, P49841, Q99941, Q16539 | IL1B, NOTCH1, HSPA8, NDUFA5, SDHD, ATP5G1, COX6A1, VDAC2, GSK3B, CREBL1, MAPK14 | More | | Meclizine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.12E-04 | 15 | P49841, Q16718, O14521, P13073, Q06055, O75460, P18848, Q13561, P05141, P20333, Q16539, P01584, Q08752, O15020, P0DP24 | GSK3B, NDUFA5, SDHD, COX4I1, ATP5G2, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, IL1B, PPID, SPTBN2, CALM2 | More | | Meclizine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Meclizine | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | | Meclizine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.85E-03 | 5 | Q16539, P09341, P25024, P25025, P07948 | MAPK14, CXCL1, CXCR1, CXCR2, LYN | More | | Meclizine | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | | Meclizine | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Meclizine | hsa05140 | Leishmaniasis | 1.46E-03 | 8 | P13612, O75015, P13765, O60603, P01375, P49006, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MARCKSL1, MAPK14, NCF4 | More | | Meclizine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Meclizine | hsa05144 | Malaria | 7.25E-04 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Meclizine | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | | Meclizine | hsa05146 | Amoebiasis | 5.02E-03 | 8 | P09341, P14778, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Meclizine | hsa05150 | Staphylococcus aureus infection | 1.91E-02 | 4 | Q14532, P59665, P59666, P49913 | KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | | Meclizine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Meclizine | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | Meclizine | hsa05163 | Human cytomegalovirus infection | 1.87E-03 | 10 | P01375, P63218, P50151, Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | TNF, GNG5, GNG10, ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Meclizine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Meclizine | hsa05168 | Herpes simplex virus 1 infection | 4.79E-02 | 8 | P25963, Q07955, Q01130, Q9Y2A4, P51522, P17038, P52738, O75820 | NFKBIA, SFRS1, SFRS2, ZNF443, ZNF83, ZNF43, ZNF140, ZNF189 | More | | Meclizine | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Meclizine | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | Meclizine | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | Meclizine | hsa05202 | Transcriptional misregulation in cancer | 1.94E-03 | 14 | P14780, P27930, Q15744, Q16548, Q13077, P08069, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, IGF1R, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Meclizine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Meclizine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Meclizine | hsa05205 | Proteoglycans in cancer | 1.15E-02 | 5 | Q12955, Q14247, P17252, P08069, P08962 | ANK3, CTTN, PRKCA, IGF1R, CD63 | More | | Meclizine | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | Meclizine | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Meclizine | hsa05212 | Pancreatic cancer | 4.45E-03 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | Meclizine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Meclizine | hsa05214 | Glioma | 9.95E-03 | 1 | P08069 | IGF1R | More | | Meclizine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | Meclizine | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | | Meclizine | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Meclizine | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | Meclizine | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Meclizine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | Meclizine | hsa05224 | Breast cancer | 1.24E-02 | 5 | P08069, P49841, Q92837, P04637, P24522 | IGF1R, GSK3B, FRAT1, TP53, GADD45A | More | | Meclizine | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | Meclizine | hsa05226 | Gastric cancer | 4.33E-03 | 5 | Q02750, O15169, P84022, Q13485, P10415 | MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | | Meclizine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.47E-04 | 9 | O95267, P07766, P20963, P09693, P06239, O60603, Q16539, Q9HC35, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, MAPK14, EML4, CD4 | More | | Meclizine | hsa05310 | Asthma | 1.25E-03 | 4 | P13765, P29965, P12724, P01375 | HLA-DOB, CD40LG, RNASE3, TNF | More | | Meclizine | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Meclizine | hsa05321 | Inflammatory bowel disease | 3.16E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Meclizine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Meclizine | hsa05330 | Allograft rejection | 1.76E-03 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | | Meclizine | hsa05332 | Graft-versus-host disease | 4.38E-03 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Meclizine | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | Meclizine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | | Meclizine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Meclizine | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Meclizine | hsa05418 | Fluid shear stress and atherosclerosis | 2.64E-03 | 7 | Q16539, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | | |